Drug treatment for melanoma: progress, but who pays?

Richard F Kefford
Med J Aust 2012; 197 (9): . || doi: 10.5694/mja12.11469
Published online: 5 November 2012

In reply: The letters of Morgan and Fullerton correctly emphasise the importance of palliative care in the management of patients with metastatic melanoma. They also draw attention to the immense cost of new drugs for melanoma, and their limited efficacy in life extension — something I also emphasised.1 Much ignored in this debate is the rapid and dramatic improvement in quality of life experienced by nearly all melanoma patients on BRAF inhibitors,2 an example of where medical oncology and palliative care should, and must, work hand in hand in optimising patient comfort. We strive toward this goal in our multidisciplinary teams. However, it is in the adjuvant setting that the new antimelanoma drugs are likely to show large improvements in survival and where reimbursement of drug costs will become an increasing challenge.

  • Richard F Kefford

  • University of Sydney at Westmead Hospital, Sydney, NSW.

Competing interests:

I have received institutional reimbursement for membership of advisory boards on drug development from Roche, GlaxoSmithKline and Bristol-Myers Squibb and travel assistance from GlaxoSmithKline to present clinical trial data.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.